Cytomegalovirus glycoprotein vaccine - GlaxoSmithKline

Drug Profile

Cytomegalovirus glycoprotein vaccine - GlaxoSmithKline

Alternative Names: GSK 1492903A; GSK Biologicals' recombinant CMV gB vaccine

Latest Information Update: 17 Feb 2012

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Cytomegalovirus vaccines; Glycopeptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Phase I Cytomegalovirus infections

Most Recent Events

  • 27 Jan 2012 GlaxoSmithKline re-initiates enrolment in a phase I trial in Healthy volunteers in Belgium (NCT01357915)
  • 22 Sep 2011 GlaxoSmithKline completes enrolment in its phase I trial in Healthy volunteers in Belgium (NCT01357915)
  • 01 Jul 2011 GlaxoSmithKline initiates enrolment in a phase I trial in Healthy volunteers in Belgium (NCT01357915)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top